Streetbeat News

Regulatory

COIN

XRPUSD

A U.S. District Judge ruled that the sale of the XRP token by Ripple is not an offer of “investment contracts”, and therefore not a security. This ruling has led to a significant increase in the price of XRP and has resulted in cryptocurrency exchanges, including Coinbase Global, adding the token back after prior delistings. The case between the SEC and Ripple remains active.

Portfolio Pulse from Chris Katje

July 13, 2023 | 9:09 pm

BTCUSD

ETHUSD

FTX Debtors have launched an online claims portal for customers, according to Reuters. The portal will allow customers to file claims related to their investments in cryptocurrencies such as Bitcoin (BTCUSD) and Ethereum (ETHUSD).

Portfolio Pulse from Charles Gross

July 13, 2023 | 9:08 pm

AZYO

Aziyo Biologics has announced a voluntary recall of its viable bone matrix products that were treated with a product from a single donor lot. The company has not provided any details on the reason for the recall or its potential impact.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 8:32 pm

ATOS

Atossa Therapeutics, Inc. (NASDAQ:ATOS) has regained compliance with the Nasdaq minimum closing bid price requirement for continued listing on The Nasdaq Capital Market. The company was previously not in compliance due to its common stock failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has made significant progress with its (Z)-endoxifen development program and has over $100 million cash with no debt.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 8:18 pm

SLQT

SelectQuote, Inc. (NYSE:SLQT) announced that its full-service medication management pharmacy, SelectRx, has received Patient-Centered Pharmacy Home accreditation from The Compliance Team (TCT), a Medicare-approved accreditation organization. This accreditation validates SelectRx's advanced pharmacy practices for chronically ill patients. Since its launch in 2021, SelectRx has grown from serving 2,000 members to over 45,000 members nationwide.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 8:16 pm

THRX

Theseus Pharmaceuticals is prioritizing the development of its fourth-generation EGFR inhibitor, THE-349, for EGFR mutant non-small cell lung cancer. The company plans to submit an Investigational New Drug (IND) application for the drug in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 8:13 pm

IEI

The US federal deficit has increased by 170% to $1.39 trillion for the nine months through June, according to Treasury Department data. The cost of managing US government debt has risen by 25% to $652 billion in the first nine months of the fiscal year. The rise in interest rates has played a significant role in driving the deficit. The value of US Treasury bonds maturing in the next three to seven years, as monitored by the iShares 3-7 Year Treasury Bond ETF (NASDAQ:IEI), is 10% lower than it was at the beginning of 2022.

Portfolio Pulse from Piero Cingari

July 13, 2023 | 8:13 pm

THRX

Theseus Pharmaceuticals has announced its decision to discontinue enrollment in its Phase 1/2 study and terminate the development of THE-630 for patients with GIST. The company's CEO expressed disappointment as they believed the therapy could have significant clinical benefits.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 8:09 pm

VTGN

Vistagen Therapeutics (NASDAQ:VTGN) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to the use of AV-101 for reduction of dyskinesia induced by levodopa, a common treatment for Parkinson's disease. The patent, once granted, will not expire until at least 2034. The U.S. Patent and Trademark Office has already granted a related U.S. patent for Vistagen's AV-101. Preclinical data shows AV-101 significantly reduced levodopa-induced dyskinesias without adverse side effects.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 8:08 pm

CRBU

Caribou Biosciences has reported clinical data from the dose escalation portion of its ANTLER Phase 1 trial. The data shows a 94% overall response rate, a 69% complete response rate, and a 44% complete response rate at 6 months or more following a single dose of CB-010. The longest complete response maintained to date is 24 months. The LBCL patient subgroup had a 50% complete response rate at 6 months or more, with the longest LBCL subgroup complete response maintained to date being 18 months.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 8:02 pm